Journal article
Phase II Study of Lapatinib in Recurrent or Metastatic Epidermal Growth Factor Receptor and/or erbB2 Expressing Adenoid Cystic Carcinoma and Non–Adenoid Cystic Carcinoma Malignant Tumors of the Salivary Glands
Abstract
PURPOSE: Expression of erbB2 and/or epidermal growth factor receptor (EGFR) is associated with biologic aggressiveness and poor prognosis in malignant salivary gland tumors (MSGTs). This phase II study was conducted to determine the antitumor activity of lapatinib, a dual inhibitor of EGFR and erbB2 tyrosine kinase activity, in MSGTs.
PATIENTS AND METHODS: Patients with progressive, recurrent, or metastatic adenoid cystic carcinoma (ACC) …
Authors
Agulnik M; Cohen EWE; Cohen RB; Chen EX; Vokes EE; Hotte SJ; Winquist E; Laurie S; Hayes DN; Dancey JE
Journal
Journal of Clinical Oncology, Vol. 25, No. 25, pp. 3978–3984
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
September 1, 2007
DOI
10.1200/jco.2007.11.8612
ISSN
0732-183X
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
Adaptor Proteins, Signal TransducingAdultAgedAged, 80 and overBiomarkers, TumorCarcinoma, Adenoid CysticDisease-Free SurvivalEpidermal Growth FactorFemaleFollow-Up StudiesHumansLapatinibMaleMiddle AgedNeoplasm Recurrence, LocalProtein-Tyrosine KinasesQuinazolinesSalivary Gland NeoplasmsTreatment Outcome